Cargando…

Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial

This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.

Detalles Bibliográficos
Autores principales:	Dahlgren, M. Kathryn, Sagar, Kelly A., Lambros, Ashley M., Smith, Rosemary T., Gruber, Staci A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429743/ https://www.ncbi.nlm.nih.gov/pubmed/33146684 http://dx.doi.org/10.1001/jamapsychiatry.2020.3567

Ejemplares similares

Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial
por: Dahlgren, Mary Kathryn, et al.
Publicado: (2022)

Made from concentrate? A national web survey assessing dab use in the United States
por: Sagar, Kelly A., et al.
Publicado: (2018)

Assessing Cannabis Use Disorder in Medical Cannabis Patients: Interim Analyses from an Observational, Longitudinal Study
por: Sagar, Kelly A., et al.
Publicado: (2021)

Recreational cannabis use impairs driving performance in the absence of acute intoxication
por: Dahlgren, M. Kathryn, et al.
Publicado: (2020)

A survey of medical cannabis use during perimenopause and postmenopause
por: Dahlgren, M. Kathryn, et al.
Publicado: (2022)

Increased White Matter Coherence Following Three and Six Months of Medical Cannabis Treatment
por: Dahlgren, Mary Kathryn, et al.
Publicado: (2022)

CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure
por: Lambros, Ashley M., et al.
Publicado: (2023)

Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants
por: Borges, Rosivaldo S., et al.
Publicado: (2013)

Toxicological Properties of Δ(9)-tetrahydrocannabinol and Cannabidiol
por: Černe, Katarina
Publicado: (2020)

Continuous-Flow Synthesis of Δ(9)-Tetrahydrocannabinol and Δ(8)-Tetrahydrocannabinol from Cannabidiol
por: Bassetti, Benedetta, et al.
Publicado: (2023)

Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract
por: Wakshlag, Joseph J., et al.
Publicado: (2020)

The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment
por: Gruber, Staci A., et al.
Publicado: (2018)

Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke
por: Hindelang, Pascal, et al.
Publicado: (2022)

Δ(9)-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure
por: Miller, Sally, et al.
Publicado: (2018)

Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms
por: Casarett, David J., et al.
Publicado: (2019)

Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
por: Henson, Jeremy D., et al.
Publicado: (2022)

Cannabidiol and Tetrahydrocannabinol Use in Parkinson’s Disease: An Observational Pilot Study
por: Sousa, Amber, et al.
Publicado: (2023)

Cannabidiol Does Not Convert to Δ(9)-Tetrahydrocannabinol in an In Vivo Animal Model
por: Wray, Louise, et al.
Publicado: (2017)

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

Cannabis, Cannabidiol Oils and Tetrahydrocannabinol—What Do Veterinarians Need to Know?
por: De Briyne, Nancy, et al.
Publicado: (2021)

Marijuana use in children: An update focusing on pediatric tetrahydrocannabinol and cannabidiol use
por: Stoner, Michael J., et al.
Publicado: (2022)

Comparative Metabolomic Profiling of the Metabolic Differences of Δ9-Tetrahydrocannabinol and Cannabidiol
por: Rao, Qianru, et al.
Publicado: (2022)

Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study
por: Varadi, Gyula, et al.
Publicado: (2022)

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans
por: Nahler, Gerhard, et al.
Publicado: (2017)

Combinations of Cannabidiol and Δ(9)-Tetrahydrocannabinol in Reducing Chemotherapeutic Induced Neuropathic Pain
por: Sepulveda, Diana E., et al.
Publicado: (2022)

Effects of Full-Spectrum Cannabis Oil with a Cannabidiol:Tetrahydrocannabinol 2:1 Ratio on the Mechanisms Involved in Hepatic Steatosis and Oxidative Stress in Rats Fed a Sucrose-Rich Diet
por: Degrave, Valentina, et al.
Publicado: (2023)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion
por: Boggs, Douglas Lee, et al.
Publicado: (2016)

Single and Synergistic Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity
por: Samarut, Éric, et al.
Publicado: (2019)

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
por: Schräder, N.H.B., et al.
Publicado: (2018)

Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101
por: Stollenwerk, Todd M., et al.
Publicado: (2021)

Neuronal and Astrocytic Morphological Alterations Driven by Prolonged Exposure with Δ9-Tetrahydrocannabinol but Not Cannabidiol
por: Landucci, Elisa, et al.
Publicado: (2022)

α-Glucosidase inhibitory activity of cannabidiol, tetrahydrocannabinol and standardized cannabinoid extracts from Cannabissativa
por: Suttithumsatid, Wiwit, et al.
Publicado: (2022)

Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function
por: Gruber, Staci A., et al.
Publicado: (2016)

Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity
por: Gruber, Staci A., et al.
Publicado: (2013)

Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study
por: Hendricks, Oliver, et al.
Publicado: (2019)

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
por: Morgan, Celia J. A., et al.
Publicado: (2018)

Cannabidiol and the Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear Memory Reconsolidation
por: Murkar, Anthony, et al.
Publicado: (2019)

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
por: Colizzi, Marco, et al.
Publicado: (2017)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_okd0u17hi6s906tpkjsbhqgg8l